Publications by authors named "Jan Willem B de Groot"

Claim this Profile
S
Safety, Feasibility, and Patient Experience of Ten-Minute Pembrolizumab Infusions: A Prospective Cohort Study.
Elianne C S de Boer, Helle-Brit Fiebrich-Westra, Gijs M M Lenis, Peter M J Plomp, Mireille A Edens, Jan Willem B de Groot

JCO Oncol Pract· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database.
Christian Menzer, Susanne Dugas-Breit, Martin Dugas, Christian U Blank, Emma J Groen, Jan Willem B de Groot

Eur J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.
Quisette P Janssen, Jacob L van Dam, Marlies L van Bekkum, Bert A Bonsing, Hendrik Bos, Jan Willem B de Groot, Bas Groot Koerkamp

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Dihydropyrimidine Dehydrogenase Enzyme-Guided Dosing of 5-Fluorouracil: Prioritizing Precision Over Dose Reduction.
Helle-Brit Fiebrich-Westra, Christina Haroun, Remco van der Galiën, Daphne den Besten-Bertholee, Maarten J Deenen, Jan Willem B de Groot

JCO Precis Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.
Mark Schuiveling, Isabella A J van Duin, Laurens S Ter Maat, Janneke C van der Weerd, Rik J Verheijden, Jan Willem B de Groot

JAMA Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Beyond Infusion: Real-World Insights Into Infusion-Related Reactions in Monoclonal Antibody Therapy.
Elise J Smolders, Elianne C S de Boer, Helle-Brit Fiebrich-Westra, Remco van der Galiën, Peter M J Plomp, Jan Willem B de Groot

JCO Oncol Pract· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Evidence on Adjuvant Chemotherapy After Resection of Left-Sided Obstructive Colon Cancer.
Bobby Zamaray, Jan Willem B de Groot, Jeanin E van Hooft, Niels F M Kok, Peter D Siersema

Clin Colorectal Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Infusion: Real-World Insights Into Infusion-Related Reactions in Monoclonal Antibody Therapy.
Elise J Smolders, Elianne C S de Boer, Helle-Brit Fiebrich-Westra, Remco van der Galiën, Peter M J Plomp, Jan Willem B de Groot

JCO Oncol Pract· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resectability stages of pancreatic cancer: nationwide reference.
Thomas F Stoop, Ingmar F Rompen, Mahsoem Ali, Bas Groot Koerkamp, Bert A Bonsing, Jan Willem B de Groot

Br J Surg· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Treatment of Patients With GI Cancer Using Pre-emptive Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil.
Helle-Brit Fiebrich-Westra, Christina Haroun, Remco van der Galiën, Daphne den Besten-Bertholee, Maarten J Deenen, Jan Willem B de Groot

JCO Precis Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: 'Enhancing patient-centered care and addressing psychosocial needs in colorectal cancer: The role of the ABCRC tool'.
Britt J M Thomassen, Merel L Kimman, Anne M J Somers, Rudolf W H M Ponds, Jan Willem T Dekker, Jan Willem B de Groot

Eur J Surg Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic parameters on baseline and early [F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.
Bernies van der Hiel, Berlinda J de Wit-van der Veen, Alfons J M van den Eertwegh, Wouter V Vogel, Marcel P M Stokkel, Jan Willem B de Groot

EJNMMI Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.
Saskia de Groot, Hedwig M Blommestein, Brenda Leeneman, Carin A Uyl-de Groot, John B A G Haanen, Jan Willem B de Groot

Med Decis Making· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Real-World Data for Machine-Learning Algorithms to Predict the Treatment Response in Advanced Melanoma: A Pilot Study for Personalizing Cancer Care.
Richard M Brohet, Elianne C S de Boer, Joram M Mossink, Joni J N van der Eerden, Alexander Oostmeyer, Jan Willem B de Groot

JCO Clin Cancer Inform· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exhaled breath analysis with the use of an electronic nose to predict response to immune checkpoint inhibitors in patients with metastatic melanoma: melaNose trial.
Brigit van Dijk, Ivonne J H Schoenaker, Astrid A M van der Veldt, Jan Willem B de Groot

Front Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model.
Hedwig M Blommestein, Saskia de Groot, Brenda Leeneman, Carin A Uyl-de Groot, John B A G Haanen, Jan Willem B de Groot

Eur J Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma.
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance, Jan Willem B de Groot

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.
Marinde J G Bond, Karen Bolhuis, Olaf J L Loosveld, Jan Willem B de Groot, Helga Droogendijk

JAMA Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Christian U Blank, Minke W Lucas, Richard A Scolyer, Bart A van de Wiel, Alexander M Menzies, Jan-Willem B de Groot

N Engl J Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.
Manja Bloem, Olivier J van Not, Maureen J B Aarts, Franchette W P J van den Berkmortel, Christian U Blank, Jan-Willem B de Groot

Int J Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma.
Isabella A J van Duin, Mark Schuiveling, Laurens S Ter Maat, Wouter A C van Amsterdam, Franchette van den Berkmortel, Jan Willem B de Groot

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrahepatic perfusion and incomplete hepatic perfusion after hepatic arterial infusion pump implantation: incidence and clinical implications.
Wills F Filipe, Florian E Buisman, Stijn Franssen, Myrtle F Krul, Dirk J Grünhagen, Jan Willem B de Groot, Cecile Grootscholten, Bas Groot Koerkamp

HPB (Oxford)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.
Daan Jan Willem Rauwerdink, Olivier van Not, Melissa de Meza, Remco van Doorn, Jos van der Hage, Jan Willem B de Groot

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance, Jan Willem B de Groot

Eur J Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Lindsay V M Leek, Jessica C L Notohardjo, Karlijn de Joode, Eline L Velker, John B A G Haanen, Jan Willem B de Groot

Sci Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis